５月13日付の記事ですが10 月頃に間違いを発見！
英語で情報提供をして修正してもらった記事が12月4日付で掲載されていました。
DOI: https://doi.org/10.1016/S0140-6736(23)00955-8
会員外では読めないかもしれません。私のコメント部分を引用します。
Kumi Tsukahara, Head of the
Reproductive Health Rights Literacy
Laboratory, said she welcomed the
pill’s approval, but said the cost and
restrictions were “totally unfair”.
“Providing abortion pills in this way...will
create barriers to access for those who
need this medicine”, Tsukahara told The
Lancet. “They are violating [a woman’s]
right to access methods and information
for safe abortions as written into treaties
and human rights covenants.”
Tsukahara said she feared that many
women will give up on using the
treatment when they learn they could
have to make multiple visits to the
clinic and be kept there “at the most
physically and mentally distressing
time”. She added: “I fear that the high
fees and inaccessibility mean that the
abortion pill will not be widely used,
even after decades. And if the number
of people using them doesn’t increase,
pharmaceutical companies offering
inexpensive generics may give up on
entering the Japanese market.
ちなみに修正してもらったのは、「Previously, only surgical abortions were available in Japan, in the first 22 weeks of pregnancy.(この薬が承認される前、日本では妊娠22週まで外科的中絶しかなかった)」としていた部分。実際には妊娠12週から22週までは「外科的中絶（D&E）」ではなく「内科的中絶（膣坐薬）」しかありませんでした。その事実を示す医会情報の英訳を提供して記者と協議した結果、以下のように修正されました。
Previously, the vast
majority of abortions, which are legal
in Japan up to 22 weeks, were carried
out using surgical procedures.
